Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide is a synthetic small molecule belonging to the benzamide and sulfonamide chemical classes. It is primarily studied as an experimental compound with potential therapeutic applications, notably as an inhibitor of carbonic anhydrase 2, a zinc metalloenzyme involved in the regulation of acid-base balance and fluid secretion. The presence of a fluorine atom on the benzyl group enhances its metabolic stability and lipophilicity, which may improve drug-like properties. This compound has not been approved for any clinical use but is investigated in medicinal chemistry for its enzyme inhibitory activity[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-(2-flouro-benzyl)-4-sulfamoyl-benzamide.